We have therefore not only elucidated a potentially new mediator between CREB1 and skeletal muscle hypertrophy but also provided a potentially new target to treat muscle waste and metabolic disorders using technologies designed to manipulate DNA methylation at specific genomic loci (54). This evidence concerns the gene CREB1 and metabolic disease.